| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/20/2003 | WO2002068387A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/20/2003 | WO2002065979A3 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 02/20/2003 | WO2002032842A9 Compounds with high monoamine transporter affinity |
| 02/20/2003 | WO2002030860A9 Ketone compounds and compositions for cholesterol management and related uses |
| 02/20/2003 | WO2002029088A9 Highly expressible genes |
| 02/20/2003 | WO2002026950A3 Transferases |
| 02/20/2003 | WO2002022621B1 INTERPHENYLENE 7-OXABICYCLIC[2.2.1]HEPTANE OXAZOLES AS PROSTAGLANDIN F2a ANTAGONISTS |
| 02/20/2003 | US20030036652 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines |
| 02/20/2003 | US20030036651 As phosphodiesterase inhibitor for prophylaxis and therapy of bronchial asthma; pneumonic diseases, pulmonary emphysema, chronic obstructive pulmonary disease acute respiratory distress syndrome (ARDS), and other respiratory diseases |
| 02/20/2003 | US20030036646 Uncoupling protein polynucleotides, polypeptides, and antibodies |
| 02/20/2003 | US20030036645 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 02/20/2003 | US20030036633 DNA encoding bradykinin B1 receptor |
| 02/20/2003 | US20030036560 Methods and compositions for treating and preventing mucositis |
| 02/20/2003 | US20030036554 Oxidizing the corresponding sulfide without sulfone production to product purer omerprazole, lansoprazole, pantoprazole, rabeprazole, etc. |
| 02/20/2003 | US20030036549 Methods for treating irritable bowel syndrome |
| 02/20/2003 | US20030036548 Method for treating anhedonia using dopamine agonists |
| 02/20/2003 | US20030036543 Especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes and Alzheimer's disease. |
| 02/20/2003 | US20030036542 Derivatives of pyrimido[6.1-a]isoquinolin-4-one |
| 02/20/2003 | US20030036538 Are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest. |
| 02/20/2003 | US20030036536 Substituted benzylthioacetic acids and esters |
| 02/20/2003 | US20030036534 Naaladase inhibitors for treating retinal disorders and glaucoma |
| 02/20/2003 | US20030036526 Activating a signaling cascade comprising, introducing leptin and/or a cytokine to a receptor complex comprising gp 130, to genes in neuro- endocrine cells or cells of neuro-endocrine origin. |
| 02/20/2003 | US20030036517 Identifying accessible regions in a target RNA molecule using trans-splicing nucleic acid molecules |
| 02/20/2003 | US20030036512 A neurotrophic factor, such as brain-derived neurotrophic factor; treating leptin resistance caused hypertension, sterility, obesity, glucose metabolic abnormality, ischemic disease and growth hormone insufficiency |
| 02/20/2003 | US20030036507 Urocortin-III and uses thereof |
| 02/20/2003 | US20030036501 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 02/20/2003 | US20030036184 Polypeptides exhibiting PDE7 activity and their use for selecting compounds which inhibit PDE 7 enzyme activity |
| 02/20/2003 | US20030036175 Depletion or removal of endotoxins from solution; obtain solution, incubate with chromatographic column, elute, recover endotoxin free solution |
| 02/20/2003 | US20030036172 Polypeptide for use in the treatment of cancerous, angiogenesis, inflammatory shock and autoimmune diseases |
| 02/20/2003 | US20030036171 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 02/20/2003 | US20030036170 Fusion polypeptides of human serum albumin and a therapeutically active polypeptide |
| 02/20/2003 | US20030036166 ErbB4 receptor-specific neuregulin related ligands and uses therefor |
| 02/20/2003 | US20030036112 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders |
| 02/20/2003 | US20030036076 CADs as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | US20030036075 Nucleotide sequences coding transport protein for us in the treatment and diagnosis of cancer, arthritis, vision defects and skin dsorders |
| 02/20/2003 | US20030035819 Skin care composition that mediates cell to cell communication |
| 02/20/2003 | US20030035799 Glycosylated antibody |
| 02/20/2003 | US20030035794 Gene-therapeutic nucleic acid construct, production of same and use of same in the treatment of heart disorders |
| 02/20/2003 | US20030035789 Purging lymphocytes |
| 02/20/2003 | CA2810339A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | CA2763913A1 Antigen binding domains |
| 02/20/2003 | CA2607992A1 Bicyclic compound, production and use thereof |
| 02/20/2003 | CA2462200A1 Peptidomimetics of biologically active metallopeptides |
| 02/20/2003 | CA2459071A1 Use of inhibitors of heparin-binding epidermal growth factor or inhibitors of its receptors for the preparation of drugs useful for treating myeloma |
| 02/20/2003 | CA2457624A1 Nutrient therapy for immuno-compromised patients |
| 02/20/2003 | CA2457433A1 Novel alpha adrenergic agents |
| 02/20/2003 | CA2456965A1 A medicine for osteoarthritis |
| 02/20/2003 | CA2456942A1 Compositions and methods for modulation of darpp-32 phosphorylation |
| 02/20/2003 | CA2456939A1 Carbonic anhydrase inhibitors |
| 02/20/2003 | CA2456909A1 Methods for the treatment and prognosis of leukemia and other cancer types |
| 02/20/2003 | CA2456881A1 Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use |
| 02/20/2003 | CA2456762A1 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | CA2456754A1 Benzazepine derivative, process for producing the same, and use |
| 02/20/2003 | CA2456744A1 Adenosine a3 receptor agonists |
| 02/20/2003 | CA2456723A1 Inhibitors of her3 activity |
| 02/20/2003 | CA2456706A1 Drug release system for controlled therapy |
| 02/20/2003 | CA2456607A1 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | CA2456599A1 Spiro compounds |
| 02/20/2003 | CA2456594A1 Preventives/remedies for cholinergic neuropathy |
| 02/20/2003 | CA2456533A1 Histone deacetylase enzyme-inhibiting derivatives of hydroxamic acid as new cytokine synthesis-inhibiting anti-inflammatory drugs |
| 02/20/2003 | CA2456369A1 Proteins associated with cell growth, differentiation, and death |
| 02/20/2003 | CA2456291A1 Hydroxamic acid derivatives |
| 02/20/2003 | CA2456271A1 Use of lysyl oxidase inhibitors for cell culture and tissue engineering |
| 02/20/2003 | CA2456250A1 Arylsulfonyl derivatives with 5-ht6 receptor affinity |
| 02/20/2003 | CA2456247A1 Use of il-18 inhibitors in hypersensitivity disorders |
| 02/20/2003 | CA2456236A1 Methods of screening based on the egf receptor crystal structure |
| 02/20/2003 | CA2456175A1 Benzoquinone ansamycins |
| 02/20/2003 | CA2456124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | CA2456103A1 Salts of substituted 1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid derivatives |
| 02/20/2003 | CA2456034A1 Sustained-release medicines |
| 02/20/2003 | CA2455871A1 Substituted pyridin-4-ones and their use as gonadotropin-releasing hormone receptor antagonists. |
| 02/20/2003 | CA2455861A1 Sulfonamide derivatives as gamma secretase inhibitors |
| 02/20/2003 | CA2455761A1 Artichoke leaf extracts |
| 02/20/2003 | CA2455759A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 02/20/2003 | CA2455754A1 Amine derivatives |
| 02/20/2003 | CA2455631A1 Aminoisoxazole derivatives active as kinase inhibitors |
| 02/20/2003 | CA2455585A1 Compounds for treating anhedonia |
| 02/20/2003 | CA2455336A1 Peptides that bind to atherosclerotic lesions |
| 02/20/2003 | CA2454768A1 Molecule |
| 02/20/2003 | CA2454648A1 Irinotecan for treatment of cancer |
| 02/20/2003 | CA2454643A1 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 02/20/2003 | CA2454640A1 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 02/20/2003 | CA2454637A1 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 02/20/2003 | CA2454627A1 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 02/20/2003 | CA2454519A1 Hprp4s as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454514A1 Sphks as modifiers of the p53 pathway and methods of use |
| 02/20/2003 | CA2454417A1 Novel benzo-fused heterocycles as endothelin antagonists |
| 02/20/2003 | CA2454251A1 Isolation and mobilization of stem cells expressing vegfr-1 |
| 02/20/2003 | CA2454173A1 Stabilized oral suspension formulation |
| 02/20/2003 | CA2454072A1 Crystalline forms of fluvastatin sodium |
| 02/20/2003 | CA2453995A1 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | CA2453890A1 Crystal and process for producing the same |
| 02/20/2003 | CA2453884A1 Micronutrient phosphates as dietary and health supplements |
| 02/20/2003 | CA2453537A1 Therapeutic 1h-pyrido¬4,3-b|indoles |
| 02/20/2003 | CA2453485A1 Pramipexole for the treatment of adhd |
| 02/20/2003 | CA2453219A1 Therapeutically useful tetracyclic ligands |
| 02/20/2003 | CA2452803A1 Tricyclic imidazopyridines |
| 02/20/2003 | CA2452488A1 Electrodes coated with treating agent and uses thereof |
| 02/20/2003 | CA2450777A1 Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia |
| 02/20/2003 | CA2428822A1 Modulators of p-selectin glycoprotein ligand 1 |